跳至主要内容
临床试验/ISRCTN11630542
ISRCTN11630542已完成未知

Assessment of clinico-radiological outcome in disseminated cysticercosis after albendazole therapy - a prospective evaluation

King George's Medical University0 个研究点目标入组 29 人开始时间: 2019年9月28日最近更新:
适应症

试验速览

阶段
未知
状态
已完成
入组人数
29

研究概览

简要总结

2020 results in https://pubmed.ncbi.nlm.nih.gov/32171260/ (added 23/11/2020)

研究设计

研究类型
Interventional

入排标准

性别
All

入选标准

  • •All consecutive patients diagnosed with disseminated cysticercosis were included in the study. A diagnosis of cysticercosis was made on the basis of the established diagnostic criteria. Disseminated cysticercosis was defined as the presence of multiple (= 3) cystic viable lesions in the brain, along with evidence of involvement of at least one extra site, like subcutaneous tissues, skeletal muscles, eyes, or presence in any visceral organ.

排除标准

  • •1. Patients with disseminated cysticercosis having features suggestive of cysticercal encephalitis. Cysticercal encephalitis was diagnosed if the patient had signs of raised intracranial pressure, like papilledema, severe headache, altered sensorium, heavy first-contact lesion load, and generalized cerebral edema
  • •2. Patients with malignancy, tuberculosis, hepatitis B or hepatitis C virus positivity, human immunodeficiency virus infection, hepatic involvement, focus of any pyogenic infection, and pregnancy
  • •3. Patients with a known hypersensitivity to albendazole in childhood, or those who had been administered albendazole, with or without corticosteroids, in the past 6 months

研究者

相似试验